Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 10Other hematologic neoplasm 2

Conditions

Recurrence 1Lymphoma, T-Cell 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Large Granular Lymphocytic 1

Interventions

venetoclax 136Cytarabine 106Cyclophosphamide 104Specimen Handling 94fludarabine 86Azacitidine 84Biopsy 71Rituximab 45Methotrexate 42Daunorubicin 41fludarabine phosphate 40Vincristine 35Magnetic Resonance Spectroscopy 35Dexamethasone 35blinatumomab 31Injections 31Decitabine 31Granulocyte Colony-Stimulating Factor 29Mycophenolic Acid 28Whole-Body Irradiation 27Idarubicin 27ibrutinib 26Tacrolimus 26Prednisone 26Etoposide 26Busulfan 25Melphalan 24Doxorubicin 24acalabrutinib 23Calcium Dobesilate 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
duvelisib × Other hematologic neoplasm × 90 days × Clear all
NCT05010005 2026-04-09

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 1 Recruiting
70 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Leukemia, Large Granular Lymphocytic

NCT03534323 2026-03-23

Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

Dana-Farber Cancer Institute

Phase 1/2 Active not recruiting
55 enrolled 14 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡